Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Lilly Asia Ventures
AddedFeb 13, 2024
UpdatedJul 16, 2026
Lilly Asia Ventures

Lilly Asia Ventures

Operating

Lilly Asia Ventures: A pioneering biomedical venture capital firm, independently managing investments since 2008.

Location
Shanghai, Shanghai, CN
Founded
2008
Firm
Compare
Portfolio
Employees

Investments

Comanche Biopharma
Comanche Biopharma

Total Raised

$111.1M

Rounds

2

Series B$75MJanuary 2024
Series A$36.1MMay 2023
Synnovation Therapeutics
Synnovation Therapeutics

Total Raised

$139M

Rounds

3

Series A$102MDecember 2023
Precede Biosciences
Precede Biosciences

Total Raised

$57M

Rounds

1

Series A$57MOctober 2023
Akura Medical
Akura Medical

Total Raised

$60M

Rounds

2

Series B$35MOctober 2023
Adarx Pharmaceuticals
Adarx Pharmaceuticals

Total Raised

$332M

Rounds

5

Series C$200MAugust 2023
Series B$46MJanuary 2023
Series B$75MSeptember 2021
Rgenta Therapeutics
Rgenta Therapeutics

Total Raised

$116.9M

Rounds

6

Series A$52MNovember 2022
Seed$18MMay 2021
Sonoma Biotherapeutics
Sonoma Biotherapeutics

Total Raised

$365M

Rounds

4

Series B$265MAugust 2021
Series A$30MSeptember 2020
Insilico Medicine
Insilico Medicine

Total Raised

$401.3M

Rounds

11

Series C$255MJune 2021
Series B$37MSeptember 2019
Synthekine
Synthekine

Total Raised

$289.5M

Rounds

3

Series B$107.5MJune 2021
NiKang Therapeutics
NiKang Therapeutics

Total Raised

$260M

Rounds

3

Series C$200MMay 2021
Series B$50MSeptember 2020
Fortis Therapeutics
Fortis Therapeutics

Total Raised

$58M

Rounds

2

Series A$40MMarch 2021
Regor Therapeutics
Regor Therapeutics

Total Raised

$140M

Rounds

3

Series B$90MFebruary 2021
Terns Pharmaceuticals
Terns Pharmaceuticals
Public

Total Raised

$348.3M

Rounds

6

Series C$87MJanuary 2021
Dmed
Dmed

Total Raised

$214M

Rounds

5

Series C$100MDecember 2020
Series B$50MOctober 2019
Sonoma Pharmaceuticals
Sonoma Pharmaceuticals
Public

Total Raised

$77.9M

Rounds

5

Post Ipo Equity$70MSeptember 2020
Legend Biotech
Legend Biotech
Public

Total Raised

$750.5M

Rounds

4

Series A$150.4MApril 2020
Ansun Biopharma
Ansun Biopharma
Public

Total Raised

$213.1M

Rounds

7

Series B$100MOctober 2019